Weekly Investment Analysts’ Ratings Changes for Smith & Nephew (SNN)

A number of firms have modified their ratings and price targets on shares of Smith & Nephew (NYSE: SNN) recently:

• 5/7/2022 – Smith & Nephew was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 4/29/2022 – Smith & Nephew was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 4/29/2022 – Smith & Nephew had its price target raised by analysts at UBS Group AG from GBX 1,200 ($14.79) to GBX 1,295 ($15.97).
• 4/23/2022 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 4/12/2022 – Smith & Nephew was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 4/6/2022 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 3/31/2022 – Smith & Nephew is now covered by analysts at StockNews.com. They set a “strong-buy” rating on the stock.
• 3/31/2022 – Smith & Nephew was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “
• 3/15/2022 – Smith & Nephew is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating on the stock.

SNN stock opened at $30.61 on Wednesday. The firm has a 50 day moving average of $32.22 and a 200-day moving average of $33.48. Smith & Nephew plc has a 12-month low of $30.23 and a 12-month high of $44.47. The company has a current ratio of 2.08, a quick ratio of 1.21 and a debt-to-equity ratio of 0.51.

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 11th. Stockholders of record on Friday, April 1st will be given a dividend of $0.288 per share. The ex-dividend date is Thursday, March 31st. This represents a dividend yield of 2.3%.

Institutional investors have recently modified their holdings of the stock. Verition Fund Management LLC raised its position in shares of Smith & Nephew by 7.6% during the 3rd quarter. Verition Fund Management LLC now owns 171,900 shares of the medical equipment provider’s stock worth $5,903,000 after purchasing an additional 12,071 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Smith & Nephew by 2.0% in the 4th quarter. Russell Investments Group Ltd. now owns 51,124 shares of the medical equipment provider’s stock valued at $1,769,000 after acquiring an additional 1,004 shares during the last quarter. Guggenheim Capital LLC raised its holdings in Smith & Nephew by 11.4% in the 3rd quarter. Guggenheim Capital LLC now owns 20,288 shares of the medical equipment provider’s stock valued at $697,000 after acquiring an additional 2,078 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Smith & Nephew in the 4th quarter valued at $31,930,000. Finally, New York State Common Retirement Fund raised its holdings in Smith & Nephew by 45.1% in the 3rd quarter. New York State Common Retirement Fund now owns 68,650 shares of the medical equipment provider’s stock valued at $2,357,000 after acquiring an additional 21,350 shares during the last quarter. Hedge funds and other institutional investors own 26.03% of the company’s stock.

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

Featured Stories